In December 2017, we entered into a collaboration agreement with Ambrx, Inc. for the development and commercialization of TRC105 (carotuximab) in China. The agreement grants Ambrx the exclusive right to develop and commercialize TRC105 in all indications (excluding ophthalmology, which are held by Santen Pharmaceutical Co., Ltd.) in China (including Hong Kong and Macau) and Taiwan. Ambrx intends to file an initial CTA with the Chinese Food and Drug Administration (CFDA) in 2018, expects to contribute to the ongoing enrollment of the Phase 3 TAPPAS trial in angiosarcoma and will lead the development of TRC105 in hepatocellular carcinoma (HCC) in China.


In September 2016, we entered into a strategic licensing collaboration with Janssen Pharmaceutica N.V., for two novel oncology assets from Janssen’s early oncology development portfolio. The agreement grants us the rights to develop TRC253 (formerly JNJ-63576253), a novel small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors which display drug resistance to currently approved treatments, which is intended for the treatment of men with prostate cancer, and TRC694 (formerly JNJ-6420694), a novel, potent, orally bioavailable inhibitor of NF-kB inducing kinase (NIK), which is intended for the treatment of patients with hematologic malignancies, including myeloma.


In March 2014, Santen Pharmaceutical Co., Ltd., a global ophthalmology company, licensed from us exclusive worldwide rights to develop and commercialize our endoglin antibodies for ophthalmology indications, including wet AMD. In June 2015, Santen filed an IND with the FDA, for the initiation of clinical studies for DE-122 in patients with wet AMD. DE-122 is the ophthalmic formulation of our proprietary endoglin antibody, TRC105. Santen is currently enrolling patients with wet AMD in a Phase 2 study comparing the combination of DE-122 with Lucentis® versus Lucentis alone.